
Say Goodbye to Heart Troubles: Oral Semaglutide from Novo Nordisk Shows 14% Decrease in Cardiovascular Risks for Adults with Type 2 Diabetes in the SOUL Trial
Welcome to the Novo Nordisk Cardiovascular Outcomes Trial Bagsværd, Denmark, 21 October 2024 Exciting News from Novo Nordisk! Today, Novo Nordisk announced the headline results from the SOUL cardiovascular outcomes trial, and it’s big news! The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of…